Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Arcturus Therapeutics Holdings

Nasdaq:ARCT
Snowflake Description

Reasonable growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ARCT
Nasdaq
$239M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • Arcturus Therapeutics Holdings has significant price volatility in the past 3 months.
ARCT Share Price and Events
7 Day Returns
31%
NasdaqGM:ARCT
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
131.6%
NasdaqGM:ARCT
1.6%
US Biotechs
-9.1%
US Market
ARCT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Arcturus Therapeutics Holdings (ARCT) 31% 17.6% 38% 131.6% - -
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • ARCT outperformed the Biotechs industry which returned 1.6% over the past year.
  • ARCT outperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
ARCT
Industry
5yr Volatility vs Market
Related Companies

ARCT Value

 Is Arcturus Therapeutics Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Arcturus Therapeutics Holdings. This is due to cash flow or dividend data being unavailable. The share price is $15.82.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Arcturus Therapeutics Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Arcturus Therapeutics Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ARCT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.15
NasdaqGM:ARCT Share Price ** NasdaqGM (2020-03-27) in USD $15.82
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Arcturus Therapeutics Holdings.

NasdaqGM:ARCT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ARCT Share Price ÷ EPS (both in USD)

= 15.82 ÷ -2.15

-7.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arcturus Therapeutics Holdings is loss making, we can't compare its value to the US Biotechs industry average.
  • Arcturus Therapeutics Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Arcturus Therapeutics Holdings's expected growth come at a high price?
Raw Data
NasdaqGM:ARCT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
16.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Arcturus Therapeutics Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Arcturus Therapeutics Holdings's assets?
Raw Data
NasdaqGM:ARCT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.70
NasdaqGM:ARCT Share Price * NasdaqGM (2020-03-27) in USD $15.82
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:ARCT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ARCT Share Price ÷ Book Value per Share (both in USD)

= 15.82 ÷ 1.70

9.29x

* Primary Listing of Arcturus Therapeutics Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arcturus Therapeutics Holdings is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Arcturus Therapeutics Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Arcturus Therapeutics Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ARCT Future Performance

 How is Arcturus Therapeutics Holdings expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Arcturus Therapeutics Holdings expected to grow at an attractive rate?
  • Arcturus Therapeutics Holdings's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Arcturus Therapeutics Holdings's earnings growth is expected to exceed the United States of America market average.
  • Arcturus Therapeutics Holdings's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ARCT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ARCT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 16.4%
NasdaqGM:ARCT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 35.5%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ARCT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ARCT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 95 15 6
2023-12-31 17 -42 6
2022-12-31 17 -40 6
2021-12-31 16 -39 6
2020-12-31 16 -44 8
2020-03-28
NasdaqGM:ARCT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 21 -6 -26
2019-09-30 25 -5 -16
2019-06-30 26 -9 -13
2019-03-31 18 -26 -22
2018-12-31 16 -21 -22
2018-09-30 10 -10 -26
2018-06-30 10 -5 -25
2018-03-31 12 1 -16
2017-12-31 13 0 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Arcturus Therapeutics Holdings's earnings are expected to grow by 16.4% yearly, however this is not considered high growth (20% yearly).
  • Arcturus Therapeutics Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ARCT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Arcturus Therapeutics Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ARCT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.17 2.10 -2.06 4.00
2023-12-31 -1.52 -0.74 -2.01 4.00
2022-12-31 -1.75 -1.56 -1.94 4.00
2021-12-31 -2.03 -1.68 -2.83 5.00
2020-12-31 -2.74 -2.20 -3.28 7.00
2020-03-28
NasdaqGM:ARCT Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.15
2019-09-30 -1.33
2019-06-30 -1.26
2019-03-31 -2.19
2018-12-31 -2.16
2018-09-30 -2.87
2018-06-30 -3.52
2018-03-31 -3.20
2017-12-31 -3.53

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Arcturus Therapeutics Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Arcturus Therapeutics Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Arcturus Therapeutics Holdings has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ARCT Past Performance

  How has Arcturus Therapeutics Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Arcturus Therapeutics Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Arcturus Therapeutics Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Arcturus Therapeutics Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Arcturus Therapeutics Holdings's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Arcturus Therapeutics Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Arcturus Therapeutics Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ARCT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 20.79 -25.99 15.06
2019-09-30 25.40 -16.01 14.31
2019-06-30 25.50 -12.83 14.24
2019-03-31 17.74 -22.10 19.02
2018-12-31 15.75 -21.79 13.28
2018-09-30 10.20 -26.05 21.28
2018-06-30 10.07 -24.98 18.81
2018-03-31 11.52 -16.25 11.62
2017-12-31 13.00 -10.90 7.57
2016-12-31 20.38 -1.57 3.45
2015-12-31 6.14 -1.90 2.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Arcturus Therapeutics Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Arcturus Therapeutics Holdings has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Arcturus Therapeutics Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Arcturus Therapeutics Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Arcturus Therapeutics Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ARCT Health

 How is Arcturus Therapeutics Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Arcturus Therapeutics Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Arcturus Therapeutics Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Arcturus Therapeutics Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Arcturus Therapeutics Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Arcturus Therapeutics Holdings Company Filings, last reported 2 months ago.

NasdaqGM:ARCT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 25.79 15.00 71.35
2019-09-30 35.90 10.02 74.17
2019-06-30 21.62 9.98 55.84
2019-03-31 6.35 9.95 31.22
2018-12-31 13.64 9.91 36.71
2018-09-30 14.15 0.00 32.83
2018-06-30 17.80 0.00 39.78
2018-03-31 33.79 0.00 48.57
2017-12-31 33.79 0.00 48.57
2016-12-31 1.58 0.13 8.35
2015-12-31
  • Arcturus Therapeutics Holdings's level of debt (58.1%) compared to net worth is high (greater than 40%).
  • Unable to establish if Arcturus Therapeutics Holdings's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Arcturus Therapeutics Holdings has sufficient cash runway for more than 3 years based on current free cash flow.
  • Arcturus Therapeutics Holdings has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 53.9% each year.
X
Financial health checks
We assess Arcturus Therapeutics Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Arcturus Therapeutics Holdings has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ARCT Dividends

 What is Arcturus Therapeutics Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Arcturus Therapeutics Holdings dividends.
If you bought $2,000 of Arcturus Therapeutics Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Arcturus Therapeutics Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Arcturus Therapeutics Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ARCT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ARCT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Arcturus Therapeutics Holdings has not reported any payouts.
  • Unable to verify if Arcturus Therapeutics Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Arcturus Therapeutics Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Arcturus Therapeutics Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Arcturus Therapeutics Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Arcturus Therapeutics Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Arcturus Therapeutics Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ARCT Management

 What is the CEO of Arcturus Therapeutics Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joe Payne
COMPENSATION $2,687,044
AGE 47
TENURE AS CEO 7 years
CEO Bio

Mr. Joseph E. Payne, also known as Joe, M.Sc., founded Arcturus Therapeutics, Inc., in 2013 and serves as its President. Mr. Payne serves as Chief Executive Officer of Arcturus Therapeutics, Inc., since March 2013. Mr. Payne served as the Chairman of the Board of Arcturus Therapeutics, Inc. until February 2, 2018 and has been its Director since March 2013. He has an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies. His background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys and Nitto Denko as evidenced by over 40 publications and patents and 7 FDA-approved IND clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.

CEO Compensation
  • Joe's compensation has increased whilst company is loss making.
  • Joe's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Arcturus Therapeutics Holdings management team in years:

1.5
Average Tenure
49
Average Age
  • The average tenure for the Arcturus Therapeutics Holdings management team is less than 2 years, this suggests a new team.
Management Team

Joe Payne

TITLE
Founder
COMPENSATION
$3M
AGE
47
TENURE
7 yrs

Pad Chivukula

TITLE
Founder
COMPENSATION
$1M
AGE
40
TENURE
7.2 yrs

Andy Sassine

TITLE
CFO & Director
COMPENSATION
$508K
AGE
55
TENURE
1.6 yrs

J.P. Headley

TITLE
Associate Director of Accounting & Operations

Neda Safarzadeh

TITLE
Director and Head of Investor Relations/Public Relations & Marketing

Jessica Mendez

TITLE
Associate Director of Human Resources

Kevin Skol

TITLE
Senior Vice President of Business Development & Alliance Management
TENURE
1.5 yrs

Steve Hughes

TITLE
Chief Development Officer
AGE
51
TENURE
0.2 yrs

Keith Kummerfeld

TITLE
VP of Finance & Corporate Controller
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure and age of the Arcturus Therapeutics Holdings board of directors in years:

1.8
Average Tenure
60
Average Age
  • The average tenure for the Arcturus Therapeutics Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Peter Farrell

TITLE
Independent Chairman of the Board
COMPENSATION
$184K
AGE
77
TENURE
1.8 yrs

Joe Payne

TITLE
Founder
COMPENSATION
$3M
AGE
47
TENURE
7 yrs

Andy Sassine

TITLE
CFO & Director
COMPENSATION
$508K
AGE
55
TENURE
0.5 yrs

James Barlow

TITLE
Independent Director
COMPENSATION
$179K
AGE
60
TENURE
1.8 yrs

Magda Marquet

TITLE
Independent Director
COMPENSATION
$177K
AGE
60
TENURE
1.8 yrs

Karah Parschauer

TITLE
Director
AGE
41
TENURE
0.8 yrs

Ed Holmes

TITLE
Independent Director
AGE
78
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
09. Dec 19 Buy Andrew Sassine Individual 05. Dec 19 05. Dec 19 5,649 $9.73 $54,965
05. Dec 19 Buy Andrew Sassine Individual 03. Dec 19 03. Dec 19 10,000 $10.00 $100,000
18. Sep 19 Buy Magda Marquet Individual 13. Sep 19 13. Sep 19 2,300 $10.58 $24,334
13. Sep 19 Buy Keith Kummerfeld Individual 12. Sep 19 12. Sep 19 500 $10.69 $5,347
30. Aug 19 Buy Joseph Payne Individual 29. Aug 19 29. Aug 19 5,000 $11.22 $56,100
26. Aug 19 Buy Andrew Sassine Individual 23. Aug 19 23. Aug 19 10,000 $10.90 $109,000
21. Aug 19 Buy Peter Farrell Individual 19. Aug 19 20. Aug 19 9,113 $11.02 $99,672
26. Jun 19 Buy Ultragenyx Pharmaceutical Inc. Company 19. Jun 19 19. Jun 19 2,400,000 $10.00 $24,000,000
X
Management checks
We assess Arcturus Therapeutics Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Arcturus Therapeutics Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ARCT News

Simply Wall St News

Investors Who Bought Arcturus Therapeutics (NASDAQ:ARCT) Shares A Year Ago Are Now Down 18%

(NASDAQ:ARCT) have tasted that bitter downside in the last year, as the share price dropped 18%. … Arcturus Therapeutics isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … In just one year Arcturus Therapeutics saw its revenue fall by 31%.

Simply Wall St -

Need To Know: Arcturus Therapeutics Ltd. (NASDAQ:ARCT) Insiders Have Been Buying Shares

So we'll take a look at whether insiders have been buying or selling shares in Arcturus Therapeutics Ltd. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'?

Simply Wall St -

What You Must Know About Arcturus Therapeutics Ltd.'s (NASDAQ:ARCT) Financial Strength

(NASDAQ:ARCT), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is ARCT will have to adhere to stricter debt covenants and have less financial flexibility. … Is ARCT right in choosing financial flexibility over lower cost of capital.

Simply Wall St -

Do Insiders Own Shares In Arcturus Therapeutics Ltd (NASDAQ:ARCT)?

The big shareholder groups in Arcturus Therapeutics Ltd (NASDAQ:ARCT) have power over the company. … Generally speaking, as a company grows, institutions will increase their ownership. … Arcturus Therapeutics is not a large company by global standards.

Simply Wall St -

ARCT Company Info

Description

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company’s pipeline of RNA therapeutics include programs to treat ornithine transcarbamylase deficiency, cystic fibrosis, glycogen storage disease type 3, hepatitis B, and non-alcoholic steatohepatitis. Its RNA therapeutics platforms could be applied toward various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. It owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 154 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Arcturus Therapeutics Holdings Inc. develops RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc.; Ultragenyx Pharmaceutical, Inc.; Takeda Pharmaceutical Company Limited; Synthetic Genomics Inc.; CureVac AG; and Cystic Fibrosis Foundation Therapeutics Inc. The company has a partnership with Duke-NUS Medical School to develop a coronavirus (COVID-19) vaccine for Singapore. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Details
Name: Arcturus Therapeutics Holdings Inc.
ARCT
Exchange: NasdaqGM
Founded: 2013
$239,482,590
15,137,964
Website: http://www.arcturusrx.com
Address: Arcturus Therapeutics Holdings Inc.
10628 Science Center Drive,
Suite 250,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ARCT New Ordinary Shares Nasdaq Global Market US USD 17. Nov 2017
Number of employees
Current staff
Staff numbers
88
Arcturus Therapeutics Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:55
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.